ELUTIA INC (ELUT)
(Delayed Data from NSDQ)
$3.19 USD
-0.01 (-0.31%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.16 -0.03 (-0.94%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.19 USD
-0.01 (-0.31%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.16 -0.03 (-0.94%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Zacks News
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
by Zacks Equity Research
Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year.
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Zacks.com featured highlights BRC, Costamare and Elutia
by Zacks Equity Research
BRC, Costamare and Elutia have been highlighted in this Screen of The Week article.
3 Best Breakout Stocks Worth a Buy for Attractive Returns
by Tirthankar Chakraborty
BRC (BRCC), Costamare (CMRE) and Elutia (ELUT) have been selected as the breakout stocks for today.
Elutia Inc. (ELUT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Elutia Inc. (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M
by Zacks Equity Research
Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.